There is no justification for the introduction of population screening.
PSA testing should be limited to men with clinical evidence of prostate cancer who have a life expectancy of more than 10 years.
Serum PSA measurement is recommended for monitoring disease progression.
The paucity of research evidence suggests that radical treatments should not be performed without the accompanying collection of pre-operative and follow-up data a coordinated programme of audit.
Conservative management is a reasonable treatment option for men with localised disease, and patients should be informed about the evidence currently available and encouraged to participate fully in decisions about their management.
There is no justification for the routine use of PSA testing in primary care.